The Shkreli Pill

• Long Palantir (PLTR): the speaker praised its results, though the stock fell about 5%; no price target was provided, so consider the pullback alongside valuation and risk.
• Alnylam (ALNY) near $160 is a cautiously positive value idea after a drop from roughly $240; monitor underlying revenue growth and pipeline progress, as the speaker gave no price target.
• The speaker said to short Tesla (TSLA) and short Micron (MU), but both calls lacked supporting analysis; Tesla was showing relative strength and Micron was rallying, making these higher-risk trades.
• Apple (AAPL) was viewed cautiously at about 34× earnings (or even the high-20s), given uncertainty over whether recent growth can persist.

• Treat UMAC as a speculative, high-expectations investment: its roughly 24.4× price-to-sales valuation depends on continued rapid growth, while losses, cash burn, and a customer representing 42% of Q2 revenue add risk.
• Watch UMAC’s next quarterly report against the cited $12 million revenue consensus; results versus its prior $16.7 million quarter may help clarify whether growth is accelerating or slowing, but avoid treating earnings as a guaranteed catalyst.
• Before investing in UMAC, verify that reported drone orders—including the $82 million PUSA order—actually translate into UMAC component sales; the discussed supplier links were not confirmed.
• Red Cat and the broader defense-drone sector may offer growth exposure, but seek evidence of actual contracts and supplier relationships rather than assuming industry demand benefits any specific company.

• Treat MRVL and LITE cautiously after their proposed $72 billion deal: both fell, and dilution and deal-closing risks remain unresolved.
• INO has a meaningful catalyst following its RRP drug approval, but wait for clarity on its cash position and any potential share offering before considering an entry.
• Avoid treating UMAC as a valuation-backed trade: the cited $10 entry and high-$20s exit lack a clear business-based rationale.
• Avoid CRBU amid its reported bankruptcy filing, and approach DRUG cautiously given the clinical hold and uncertain commercial prospects.

• Avoid Intel (INTC) as a high-risk turnaround: weak guidance and execution concerns outweigh the uncertain AI upside; the speaker’s $20 downside scenario was speculative, not a firm target.
• Hold off on buying Alphabet (GOOGL) until Search and advertising trends stabilize and investors can better assess whether its record AI spending will pay off.
• Treat Amazon (AMZN) cautiously: AWS grew 39%, but weak retail growth and heavy investment cloud the cash-flow and valuation outlook; the cited $140 model value was assumption-dependent, not a firm target.
• Monitor AMD for possible PC-market weakness following Intel’s outlook, but the discussion did not provide enough company-specific evidence for a trade.

• Consider HYDR for diversified hydrogen exposure rather than buying Bloom Energy (BE) or Plug Power (PLUG) directly; verify current holdings, fees, concentration, and distribution details before investing.
• IQE plc (IQE) is the clearest individual-stock idea, with potential support from its North Carolina manufacturing assets, MACOM’s investment, and semiconductor spending—but confirm these developments’ funding and earnings impact, as no price target or timeframe was provided.
• Approach Netlist (NLST) cautiously: its valuation and reliance on RAM resales raise questions about margins and durable licensing revenue, so review its filings before considering a position.

• Consider Merck (MRK) as the clearest favorable idea: the discussion highlighted Keytruda’s role in longer-duration treatment, but offered no price target or explicit buy recommendation.
• Treat Netlist (NLST) as a high-risk, event-driven opportunity tied to licensing and settlement payments; supply uncertainty and resale volatility remain important risks.
• Approach Humacyte (HUMA) cautiously: promising interim clinical results are offset by low revenue and uncertain hospital adoption.
• Avoid treating the speculative claims on Zura Bio (ZURA) and Ultragenyx (RARE) as substantiated forecasts; the discussion provided no supporting valuation or timeline.

• Avoid treating the prospective Anthropic IPO as a buy until the final offering price, share count, conversion terms, and compute commitments are clear; the reported growth does not settle questions about cash needs and returns.
• Approach CoreWeave and Nebius cautiously: investigate financing access, capacity utilization, and potential GPU overcapacity before investing.
• The EWZ selloff may look oversold, but the discussion offered no firm buy recommendation; political and currency risks remain high, and there was no company-specific case for PBR, NU, or MELI.

• The clearest trade view is to short Moderna (MRNA), as the speaker expects further downside; this is a high-risk opinion with no price target or timeline, so keep any position small.
• If you lack a clear investment thesis, consider holding cash rather than forcing a trade.
• Avoid highly leveraged perpetual futures: at 100x leverage, even a small adverse move can trigger liquidation; understand margin rules before trading.

• Consider a short position in Moderna (MRNA) near $230–$235, as the speaker viewed its valuation as difficult to justify without highly speculative future cancer-drug sales; this is a high-risk thesis, so monitor ESMO data on October 24 and pipeline updates.
• Watch Zura Bio (ZURA) ahead of its Q4 top-line results as a speculative catalyst-driven opportunity; positive data could support upside, but substantial Phase 3 costs may require financing and dilute shareholders.
• For exposure to the partnered cancer-vaccine opportunity, consider researching Merck (MRK) as an alternative to MRNA, while recognizing that the transcript provides no standalone valuation or price target.

The transcript offers no verified, thesis-backed trade or price target; reported orders and positions should not be treated as investment recommendations. Avoid acting on the vague MRNA short comment or the semiconductor and AI names without independent research and a clear risk plan. The key actionable lesson is to verify order status and execution, and never trade on potentially material nonpublic information.

• Treat Spruce Biosciences (SPRB) as a high-risk, catalyst-driven biotech opportunity: the discussion anticipated a BLA submission during the quarter and possible FDA action five to six months later, but approval and commercial uptake are uncertain.
• Revolution Medicines (RVMD) was viewed as potentially undervalued given its cancer-drug opportunity, but the stock has already risen substantially and no price target or timeline was provided.
• Be cautious on AST SpaceMobile (ASTS): the cited roughly $20 billion market cap against about $30 million in quarterly revenue implies a demanding valuation; wait for evidence of broader customer demand and stronger revenue.
• Avoid treating private SpaceX shares or speculative themes like robotics as reliable shortcuts; keep positions diversified and sized to withstand losses.
• For AI investments such as NVIDIA (NVDA), Intel (INTC), and Meta (META), prioritize evidence of enterprise adoption and business results over the broad AI narrative.

• Avoid chasing CoreWeave (CRWV) around $60–$62 until its debt and financing risks become clearer; treat talk of an Nvidia backstop or Oracle rescue as unconfirmed speculation.
• Approach AI infrastructure stocks selectively: compare expected revenue with capital spending and debt, since strong computing demand does not guarantee durable returns.
• Don’t infer a clinical catalyst from Moderna (MRNA)’s rally or short 10x Genomics (TXG) or Ginkgo Bioworks (DNA) on the limited discussion alone; no supported targets or timelines were provided.

• Treat CoreWeave (CRWV) as a high-risk warning for AI infrastructure: its debt and customer concentration could pressure NVIDIA (NVDA) and related suppliers; a rumored $10 billion NVIDIA investment is speculation, not a confirmed backstop.
• Avoid treating the AI semiconductor selloff as a clear buying opportunity until earnings show customers can sustain spending; the strongest risk flags are NVIDIA, SanDisk (SNDK), and Seagate (STX), with no entry levels or price targets provided.
• Watch Anthropic’s Investor Day and upcoming AI-sector earnings for volatility, but wait for clearer guidance before considering a trade.
• Liquidia (LQDA) has a potentially positive settlement catalyst that reduces the risk its drug is pulled, though restrictions may limit prescriptions; no price target or near-term direction is established.
• Monitor Disc Medicine (IRON) for its APOLLO study top-line data, expected “very soon,” but the transcript gives no firm long or short call.

The insights do not support a high-conviction buy or sell: avoid shorting SanDisk based only on the claim that it has risen, and investigate Moderna (MRNA)’s drug prospects, legal and regulatory risks, and liquidity before investing. Treat Revolution Medicines (RVMD) as a high-risk growth thesis: its cancer-drug potential is promising, but the stock has already risen substantially and no clinical or valuation evidence was provided. For AI and robotics, avoid buying a theme simply because it is popular; consider a diversified basket only after checking whether expectations are already priced in. The other examples are historical, speculative, or lack current valuation and timing details, so they do not offer actionable trades from this material.

• Spruce Biosciences (SPRB) is a high-risk, milestone-driven opportunity: track the expected BLA submission and FDA review, while recognizing that approval and commercial success in a very small patient population are uncertain.
• The apparent Liquidia (LQDA) thesis is conditional on a favorable patent appeal and continued access to its ILD indication; the cited $50+ scenario is speculative, so verify the company and current legal status before considering a trade.
• Nautilus Biotechnology (NAUT) drew a bearish short opinion, but the discussion provides too little evidence for a short thesis; investigate its revenue trajectory and product progress before acting.

• IONQ, RGTI, and QBTS: The strongest bearish view is to consider short exposure, based on concerns about monetization and the sector’s direction; these volatile stocks could rebound sharply, so manage risk.
• PLTR: Shkreli called it a short after its strong rally, but offered no price target or timing, making this a high-risk, opinion-based trade.
• ASTS: Be cautious at roughly 100× sales amid questions about capital needs, margins, and customer concentration; no target or catalyst was provided.
• LQDA: Treat the stock near $30 as an event-driven speculation, not a confirmed opportunity: a possible settlement was unconfirmed, and a decision was mentioned for November.
• For broad-market exposure, SPY or QQQ were suggested; consider a market-neutral strategy only if you understand the risks of shorting.

• Treat KOD only as a high-risk, short-term rebound trade: the discussion cites below $30 as a possible entry and below $25 as more attractive, but warns selling may continue and questions the drug’s clinical advantage and insurance coverage.
• Avoid treating those levels as validated price targets or a long-term buy case; ITCI is mentioned only as an example that a drug can succeed in a crowded market, not as a recommendation.
• Trade options cautiously: understand the strike, expiration, and delta, since inexpensive out-of-the-money calls can expire worthless.
• Evaluate any future OpenAI or other AI-company IPO on its own valuation and fundamentals; no specific listing or investment recommendation is provided.

• Intel (INTC) is the clearest bullish stock view: the speaker is long, but gave no price target or timeframe, so treat it as a limited-conviction idea.
• Watch upcoming results and spending guidance from Alphabet, Microsoft, Apple, and Amazon for signals about memory demand affecting SanDisk (SNDK), Micron (MU), and SK hynix; no confirmed catalyst was established.
• For simpler exposure, consider whether SMH (semiconductors) or SPY (the broad market) better matches your goals rather than holding several overlapping stock positions.
• Preserve capital: keep new positions small, avoid adding to losers or using leveraged ETFs, and don’t force trades while in a drawdown.

• Consider SMH as a hedge for concentrated semiconductor longs, since it was described as highly correlated with the broader market; size any hedge carefully, as it may not offset company-specific losses.
• The clearest bearish ideas were IONQ, QBTS, and RGTI, but these volatile short candidates came with no price targets or catalysts, so research and risk limits are essential.
• LRCX, ADI, and ALAB were also floated as potential semiconductor shorts against long holdings, without supporting valuation analysis.
• MRNA was called a short-term short opportunity around $213–$215, but this was a trading view without a stated target or timeframe.

Avoid shorting Twist Bioscience (TWST) solely because it looks expensive: the business is growing rapidly, though no buy target or timing was provided.
The speaker remains short Moderna (MRNA) at around $210, but offered no thesis, target, or timeframe, so this is not a well-supported trade to follow.
Do not add to Nektar Therapeutics (NKTR) based on these insights; the speaker is down about 50% and did not recommend buying more.